Cardiothoracic & vascular anesthesia
Evaluation of Postoperative Thromboembolic Events in Orthotopic Heart Transplant Patients Receiving 4-Factor Prothrombin Complex Concentrate Monotherapy Versus Combination Therapy With Very Low-Dose Recombinant Activated Factor VII: A Retrospective Cohort Study
Authors' conclusion
The addition of very low-dose rFVIIa to 4F-PCC during OHT demonstrated a non-statistically significant increase in thrombotic events.
Study context
- Population
- Adults undergoing orthotopic heart transplantation (OHT) in 2023 who received 4F-PCC for perioperative coagulopathy, tertiary academic centre, Boston
- Participants
- 56 adults
- Exposure
- 4F-PCC plus very low-dose rFVIIa vs 4F-PCC monotherapy
- Combinationn = 15
- Monotherapyn = 41reference
- Outcome
- Incidence of thromboembolic events
- Follow-up
- Within 30 days postoperatively or until discharge, whichever first
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
P = 0.32
Observational data: associations, not effects.
Original publication
Evaluation of Postoperative Thromboembolic Events in Orthotopic Heart Transplant Patients Receiving 4-Factor Prothrombin Complex Concentrate Monotherapy Versus Combination Therapy With Very Low-Dose Recombinant Activated Factor VII: A Retrospective Cohort Study. J Cardiothorac Vasc Anesth. Published 19 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →